Skip to main content
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
letter
. 2020 Jun 20;14(5):937–938. doi: 10.1016/j.dsx.2020.06.005

Letter to the editor in response to the article: “Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis (Kumar et al.)”

Awadhesh Kumar Singh , Ritu Singh
PMCID: PMC7305489  PMID: 32593934

Dear Editor,

We read the article by Kumar et al. titled “Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis” https://doi.org/10.1016/j.dsx.2020.04.044 published on May 6, 2020 in this journal with a great interest [1]. We felt that authors have put more emphasis on strength of this analysis rather than the limitation. This meta-analysis has a lot more limitations than any strength, which should have been acknowledged by the authors.

We have noted following limitations to this meta-analysis, which needs kind attention of authors to interpret it properly.

  • 1

    Authors’ have calculated the odds ratio of severity and mortality in patients with diabetes and COVID-19. However, to assess the relative risk of severity and mortality, risk ratio or hazard ratio should have been calculated, rather than the odds ratio.

  • 2

    Authors have enthusiastically included 33 studies in Table 1 [1] without seriously looking for the overlap. Repeat inclusion of same data will give erroneous results rather than the real. For example- Same one/two centers of Wuhan, China, with the same/different first author name, with data collected during same time period, have been reported in 17 studies out of 33 studies included in this meta-analysis. Moreover, the largest China-wide study reported by Guan et al. included in this metaanalysis may have included the data reported from several smaller hospital-based studies including these 17 studies. Similarly, data of Goyal et al. from USA and CDC, USA have overlapped data. We wonder how the authors have overlooked this issue while conducting this meta-analysis and not excluded these studies to avoid overlapping data, that can lead to a wrong conclusion.

  • 3

    Authors have concluded that “Diabetes in patients with COVID-19 is associated with a two-fold increase in mortality as well as severity of COVID-19, as compared to non-diabetics”. This is a factually incorrect statement. Authors need to realize that they have calculated the odds ratio of severity and mortality while comparing the diabetic patients who required mechanical ventilation or ICU admission or died versus the diabetic patient who did not. This meta-analysis did not calculate the risk of severity or mortality between patients with diabetes versus non-diabetic cohort. Therefore, the conclusion of this meta-analysis should be that “patients who have severe COVID-19, or who die from the disease, are more likely to have diabetes”, rather than diabetic patients had more severe Covid-19 and more likely to succumb to death. This needs to be clarified. There are number of meta-analysis now available that have done similar kind of analysis and compared severity and mortality in diabetic patients to another diabetic patient with less severe COVID-19 or having survived [[2], [3], [4], [5], [6]]. Authors have overlooked citing these articles. Unfortunately, none of these meta-analyses published so far including the Kumar et al. have compared the severity and fatality in diabetic vs. non-diabetic cohort with COVID-19. References: (1-6)

Declaration of competing interest

We hereby declare that we have no conflict of interest, related to this document.

References

  • 1.Kumar A, Arora A, Sharma O, et al. Is diabetes mellitus associated with mortality and severity of COVID-19? A metaanalysis. Diabetes Metabolic Syndrome: Research and Review. 10.1016/j.dsx.2020.04.044. [DOI] [PMC free article] [PubMed]
  • 2.Emami A., Javanmardi F., Pirbonyeh N., Akbari A. Prevalence of Underlying Diseases in Hospitalized Patients with COVID-19: a Systematic Review and Meta-Analysis. Arch Acad Emerg Med. 2020;8(1):e35. [PMC free article] [PubMed] [Google Scholar]
  • 3.Yang J., Zheng Y., Gou X. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis. 2020 doi: 10.1016/j.ijid.2020.03.017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Li B., Yang J., Zhao F. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020 doi: 10.1007/s00392-020-01626-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Jain V., Yuan J.M. Systematic review and meta-analysis of predictive symptoms and comorbidities for severe COVID-19 infection. medRxiv. 2020 doi: 10.1007/s00038-020-01390-7. Pre-print. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Chen Y.M., Gong X., Wang L., Guo J. Effects of hypertension, diabetes and coronary heart disease on COVID-19 diseases severity: a systematic review and meta-analysis. medRxiv. 2020 Pre-print. [Google Scholar]

Articles from Diabetes & Metabolic Syndrome are provided here courtesy of Elsevier

RESOURCES